ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-PO325

Calcimimetics Adherence and Preference in the Management of Uremic Secondary Hyperparathyroidism (SHPT) in Europe

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis


  • Nduka, Chidozie U., Amgen, Uxbridge, United Kingdom
  • Louie, Karly S., Amgen, Uxbridge, United Kingdom
  • Taylor, Jo, Dorset County Hospital NHS Foundation Trust, Dorchester, Dorset, United Kingdom
  • Hall, Matt, Nottingham University Hospitals NHS Trust, Nottingham, Nottingham, United Kingdom
  • Aucella, Filippo, Fondazione IRCCS “Casa Sollievo della Sofferenza”, San Giovanni Rotondo, Italy
  • Urena Torres, Pablo A., AURA Paris-Nord, Saint-Ouen, France
  • Labriola, Laura, Department of Nephrology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
  • Evenepoel, Pieter, Department of Immunology and Microbiology, Division of Nephrology, University Hospitals Leuven, Leuven, Belgium
  • Ma, Junjie, Amgen, Thousand Oaks, California, United States
  • Saleem, Najma, Amgen, Thousand Oaks, California, United States
  • Pisoni, Ronald L., Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
  • Fouqueray, Bruno L., Amgen GmbH, Rotkreuz, Switzerland
  • Horne, Robert, University College London School of Pharmacy, London, London, United Kingdom

Oral cinacalcet (CIN) and intravenous etelcalcetide (ETEL) are approved for treating hemodialysis (HD) patients with SHPT. Data on patient-reported outcomes and calcimimetic preference from nephrologists/nurses’ perspectives are provided in this cross-sectional study.


Patient questionnaires assessed CIN adherence (Medication Adherence Report Scale [MARS]), calcimimetic perceptions [Beliefs about Medicines Questionnaire (BMQ) and Treatment Intrusiveness Scale (TIS)] and gastrointestinal (GI) symptom experience in the month before enrolment. Nephrologists/nurse questionnaires assessed calcimimetic preference (CIN vs ETEL) based on effectiveness, side effects, patient burden and quality of life (QoL).


414 patients (204 CIN & 210 ETEL) responded to the surveys. Patient characteristics were similar between CIN vs ETEL: mean age 65 vs 64yrs; men 57% vs 61%; mean no. of medications 9 vs 8. CIN adherence was high (mean MARS 4.8), and 78% of patients reported using all CIN prescribed in the month before enrolment. There were no significant differences in perceptions of Calcimimetic Necessity (mean BMQ-Necessity CIN vs ETEL = 3.5±0.7 vs 3.6±0.5, p=0.49), Calcimimetic Concerns (mean BMQ-Concerns CIN vs ETEL = 2.3±0.6 vs 2.3±0.9, p=0.17), or treatment intrusiveness (mean TIS CIN vs ETEL= 1.6±0.7 vs 1.8±0.9). ETEL and CIN patients attributed GI symptoms to calcimimetic use at similar rates: nausea (ETEL 23%; CIN 21%); vomiting (ETEL 26%; CIN 24%) and Diarrhea (ETEL 21%; CIN 21%). Nephrologists (n=111) and nurses (n=113) preferred ETEL for patient adherence (Nephrologist 89%; Nurses 78%); reducing patient burden (Nephrologist 87%; Nurses 86%); minimizing side effects (Nephrologist 78%; Nurses 66%); improving QoL (Nephrologist 72%; Nurses 75%); and effectiveness (Nephrologist 60%; Nurses 74%).


Nephrologists/nurses preferred ETEL for encouraging patient adherence, reducing patient burden, minimizing side effects, improving QoL, and effectiveness. High levels of patient engagement were observed for ETEL and CIN.


  • Commercial Support –